Not a trial; they will exchange resources and cooperate on research.
AIPEI, Taiwan - To support in containing the COVID-19 epidemic, the Ministry of Science and Technology Taiwan (MOST) proactively promotes cooperation between the domestic academic research community and foreign academic research institutions to assist in fighting the virus SARS-CoV-2.
The Research Center for Emerging Virus Infections (RCEVI) of the Chang Gung University, supported by the Ministry of Science and Technology Taiwan, will cooperate with the Monash Biomedicine Discovery Institute (BDI) in Australia to study the effectiveness of the anti-parasitic drug "ivermctin" in inhibiting the novel coronavirus and possibly leading to the development of new antiviral drugs in the future.
The Monash Biomedicine Discovery Institute announced on April 3 that the research they carried out with the Peter Doherty Institute for Infection and Immunity found that ivermctin drugs can inhibit the growth of SARS-CoV-2 within 48 hours and help cells to clear up the virus. After the news was released, it attracted worldwide attention and heated discussion. After assessment of the case by the MOST, director Shin-Ru Shih of the RCEVI was invited as chief researcher to discuss with the Australian research team regarding the study of ivermctin.
The researchers from both parties held the first video conference on May 7. Both parties showed a very high willingness to cooperate, and together reached a consensus on specific follow-up cooperation projects. In the future, RCEVI will provide virus isolates as well as P2 / P3 laboratory equipment, while the team from Australia will provide experimental drugs to jointly study the inhibitory effect of ivermctin against SARS-CoV-2.
[-] TrumpLyftAlles | 1 points | May 14 2020 17:51:53
Not a trial; they will exchange resources and cooperate on research.
AIPEI, Taiwan - To support in containing the COVID-19 epidemic, the Ministry of Science and Technology Taiwan (MOST) proactively promotes cooperation between the domestic academic research community and foreign academic research institutions to assist in fighting the virus SARS-CoV-2.
The Research Center for Emerging Virus Infections (RCEVI) of the Chang Gung University, supported by the Ministry of Science and Technology Taiwan, will cooperate with the Monash Biomedicine Discovery Institute (BDI) in Australia to study the effectiveness of the anti-parasitic drug "ivermctin" in inhibiting the novel coronavirus and possibly leading to the development of new antiviral drugs in the future.
The Monash Biomedicine Discovery Institute announced on April 3 that the research they carried out with the Peter Doherty Institute for Infection and Immunity found that ivermctin drugs can inhibit the growth of SARS-CoV-2 within 48 hours and help cells to clear up the virus. After the news was released, it attracted worldwide attention and heated discussion. After assessment of the case by the MOST, director Shin-Ru Shih of the RCEVI was invited as chief researcher to discuss with the Australian research team regarding the study of ivermctin.
The researchers from both parties held the first video conference on May 7. Both parties showed a very high willingness to cooperate, and together reached a consensus on specific follow-up cooperation projects. In the future, RCEVI will provide virus isolates as well as P2 / P3 laboratory equipment, while the team from Australia will provide experimental drugs to jointly study the inhibitory effect of ivermctin against SARS-CoV-2.
permalink